Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma profit

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

- PMLiVE

Former Nycomed CEO Hakan Bjorklund to chair Lundbeck

Mats Pettersson to step down in March

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

- PMLiVE

Lundbeck launches Chorea Matters online resource

Includes recognising chorea education programme

- PMLiVE

Pharma’s reputation declining say patient groups

Pricing policies and a lack of transparency lead list of grievances

- PMLiVE

Lundbeck slumps as it cuts sales, profit guidance

Comes despite three new products due to hit market

- PMLiVE

EMA recommends approval for alcohol dependency drug

Lundbeck’s Selincro to be used in conjunction with psychosocial support

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links